DYNE THERAPEUTICS INC (DYN) — insider trading
Health Care · NASDAQ
DYNE THERAPEUTICS INC (DYN) has 36 reported SEC Form 4 insider transactions in our data, including 34 open-market sales among the most recent 36 (latest 2026-07-07).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 5,000 | $23.61 | $118.0K | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 11,665 | $23.62 | $275.5K | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 49,193 | $23.17 | $1.14M | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 14,844 | $23.62 | $350.6K | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 62,543 | $23.17 | $1.45M | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 29,587 | $23.62 | $698.8K | Form 4 |
| 2026-07-07 | Rhodes Jason P | Director | Open-market sale | 124,379 | $23.17 | $2.88M | Form 4 |
| 2026-07-06 | Rhodes Jason P | Director | Open-market sale | 100,019 | $22.79 | $2.28M | Form 4 |
| 2026-07-06 | Rhodes Jason P | Director | Open-market sale | 127,182 | $22.79 | $2.90M | Form 4 |
| 2026-07-06 | Rhodes Jason P | Director | Open-market sale | 253,039 | $22.79 | $5.77M | Form 4 |
| 2026-06-29 | Rhodes Jason P | Director | Open-market sale | 40,702 | $21.14 | $860.4K | Form 4 |
| 2026-06-29 | Rhodes Jason P | Director | Open-market sale | 51,756 | $21.14 | $1.09M | Form 4 |
| 2026-06-29 | Rhodes Jason P | Director | Open-market sale | 102,969 | $21.14 | $2.18M | Form 4 |
| 2026-06-26 | Rhodes Jason P | Director | Open-market sale | 64,411 | $21.28 | $1.37M | Form 4 |
| 2026-06-26 | Rhodes Jason P | Director | Open-market sale | 81,903 | $21.28 | $1.74M | Form 4 |
| 2026-06-26 | Rhodes Jason P | Director | Open-market sale | 162,954 | $21.28 | $3.47M | Form 4 |
| 2026-06-25 | Rhodes Jason P | Director | Open-market sale | 5,019 | $21.10 | $105.9K | Form 4 |
| 2026-06-25 | Rhodes Jason P | Director | Open-market sale | 6,382 | $21.10 | $134.7K | Form 4 |
| 2026-06-25 | Rhodes Jason P | Director | Open-market sale | 12,699 | $21.10 | $267.9K | Form 4 |
| 2026-06-25 | Lucera Erick | Officer (Chief Financial Officer) | Open-market sale | 2,362 | $20.37 | $48.1K | Form 4 |
| 2026-06-24 | Rhodes Jason P | Director | Open-market sale | 19,973 | $21.02 | $419.8K | Form 4 |
| 2026-06-24 | Rhodes Jason P | Director | Open-market sale | 25,397 | $21.02 | $533.8K | Form 4 |
| 2026-06-24 | Rhodes Jason P | Director | Open-market sale | 50,530 | $21.02 | $1.06M | Form 4 |
| 2026-06-23 | Rhodes Jason P | Director | Open-market sale | 30,774 | $21.13 | $650.3K | Form 4 |
| 2026-06-23 | Rhodes Jason P | Director | Open-market sale | 39,131 | $21.13 | $826.8K | Form 4 |
| 2026-06-23 | Rhodes Jason P | Director | Open-market sale | 77,855 | $21.13 | $1.65M | Form 4 |
| 2026-06-23 | Kersten Dirk | Director | Open-market sale | 1,657 | $21.47 | $35.6K | Form 4 |
| 2026-06-23 | Kersten Dirk | Director | Open-market sale | 71,629 | $21.04 | $1.51M | Form 4 |
| 2026-06-22 | Kersten Dirk | Director | Open-market sale | 190,676 | $20.57 | $3.92M | Form 4 |
| 2026-06-22 | Greene Barry E | Director | Grant / award / vesting (derivative) | 57,463 | $0.00 | $0 | Form 4 |
| 2026-06-18 | Kersten Dirk | Director | Open-market sale | 46,901 | $20.07 | $941.4K | Form 4 |
| 2026-06-17 | Kersten Dirk | Director | Open-market sale | 37,454 | $20.14 | $754.3K | Form 4 |
| 2026-06-16 | Cox John | Director, Officer (CEO & President) | Open-market sale | 2,683 | $18.33 | $49.2K | Form 4 |
| 2026-06-16 | Friedl-Naderer Johanna | Officer (Chief Commercial Officer) | Open-market sale | 145 | $18.33 | $2.7K | Form 4 |
| 2026-06-16 | Kerr Douglas | Officer (Chief Medical Officer) | Open-market sale | 887 | $18.33 | $16.3K | Form 4 |
| 2026-06-05 | HURWITZ EDWARD | Director | Grant / award / vesting (derivative) | 35,152 | $0.00 | $0 | Form 4 |
Ask the chat about DYN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: DYNE THERAPEUTICS INC (DYN).
Last updated 2026-07-07 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.